Literature DB >> 21090595

EMBM - a new enzyme mechanism-based method for rational design of chemical sites of covalent inhibitors.

Tamar Traube1, Subramaniam Vijayakumar, Michal Hirsch, Neta Uritsky, Michael Shokhen, Amnon Albeck.   

Abstract

We introduce an enzyme mechanism-based method (EMBM) aimed at rational design of chemical sites (CS) of reaction coordinate analog inhibitors. The energy of valence reorganization of CS, caused by the formation of the enzyme-inhibitor covalent complex, is accounted for by new covalent descriptors W1 and W2. We considered CS fragments with a carbonyl reactivity center, like in native protease substrates. The W1 and W2 descriptors are calculated quantum mechanically on small molecular clusters simulating the reaction core of the formed covalent tetrahedral complex, anionic TC(O-) or neutral TC(OH). The modeling on a reaction core allows generation of various CS and corresponding TC(O-) and TC(OH) as universal building blocks of real inhibitors and their covalent complexes with serine or cysteine hydrolases. Moreover, the approach avoids the need for 3D structure of the target enzyme, so EMBM may be used for ligand-based design. We have built a chemical site of inhibitors (CSI) databank with pairs of W1 and W2 descriptors precalculated for both CH₃O(-) and CH₃S(-) nucleophiles for every collected CS fragment. We demonstrated that contribution of a CS fragment to the binding affinity of an inhibitor depends on both its covalent reorganization during the chemical transformation and its noncovalent interactions in the enzyme active site. Consequently, prediction of inhibitors binding trend can be done only by accounting for all of these factors, using W1 and W2 in combination with noncovalent QSAR descriptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21090595      PMCID: PMC3010454          DOI: 10.1021/ci100330y

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  29 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.

Authors:  B Bachand; M Tarazi; Y St-Denis; J J Edmunds; P D Winocour; L Leblond; M A Siddiqui
Journal:  Bioorg Med Chem Lett       Date:  2001-02-12       Impact factor: 2.823

Review 3.  The depth of chemical time and the power of enzymes as catalysts.

Authors:  R Wolfenden; M J Snider
Journal:  Acc Chem Res       Date:  2001-12       Impact factor: 22.384

Review 4.  Mechanistic basis of enzyme-targeted drugs.

Authors:  James G Robertson
Journal:  Biochemistry       Date:  2005-04-19       Impact factor: 3.162

5.  Why enzymes are proficient catalysts: beyond the Pauling paradigm.

Authors:  Xiyun Zhang; K N Houk
Journal:  Acc Chem Res       Date:  2005-05       Impact factor: 22.384

6.  Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.

Authors:  D L Boger; H Sato; A E Lerner; M P Hedrick; R A Fecik; H Miyauchi; G D Wilkie; B J Austin; M P Patricelli; B F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  Mechanism of association of N-acetyl-L-phenylalanylglycinal to papain.

Authors:  A Frankfater; T Kuppy
Journal:  Biochemistry       Date:  1981-09-15       Impact factor: 3.162

8.  Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

Authors:  S E Webber; J Tikhe; S T Worland; S A Fuhrman; T F Hendrickson; D A Matthews; R A Love; A K Patick; J W Meador; R A Ferre; E L Brown; D M DeLisle; C E Ford; S L Binford
Journal:  J Med Chem       Date:  1996-12-20       Impact factor: 7.446

9.  Potent and selective nonpeptide inhibitors of caspases 3 and 7.

Authors:  D Lee; S A Long; J H Murray; J L Adams; M E Nuttall; D P Nadeau; K Kikly; J D Winkler; C M Sung; M D Ryan; M A Levy; P M Keller; W E DeWolf
Journal:  J Med Chem       Date:  2001-06-07       Impact factor: 7.446

10.  Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency.

Authors:  P D Edwards; D J Wolanin; D W Andisik; M W Davis
Journal:  J Med Chem       Date:  1995-01-06       Impact factor: 7.446

View more
  1 in total

1.  From sequence to enzyme mechanism using multi-label machine learning.

Authors:  Luna De Ferrari; John B O Mitchell
Journal:  BMC Bioinformatics       Date:  2014-05-19       Impact factor: 3.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.